在接受生物治疗的患者中的皮肤莱什曼病:西班牙CLINI-AEDV多中心研究
Andrea Ciudad1, Ramón M Pujol2, Fernándo Gallardo2
1Servicio de Dermatología, Hospital del Mar, Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Departament de Medicina i Ciències de la Vida (MELIS), Universitat Pompeu Fabra, Barcelona, Spain. andreaciudad33@gmail.com.
Acta dermato-venereologica
|March 12, 2026
概括
抗瘤坏死因子α (TNFα) 疗法可以触发莱什曼病. 停止这些生物药物治疗皮肤或粘膜皮肤莱什曼病并没有显著影响治愈率,这表明需要谨慎管理.
科学领域:
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
- 皮肤病学 皮肤病学
背景情况:
- 抗瘤坏死因子α (TNFα) 药物与粒状细胞感染的重新激活有关,包括莱什曼病.
- 在使用生物疗法的患者中报告了非典型或复发的皮肤雷什曼病 (CL) 和粘膜皮肤雷什曼病 (MCL).
研究的目的:
- 描述在流行地区接受生物治疗的患者中CL和MCL的临床特征和管理.
- 分析停止生物治疗对莱什曼病治愈率的影响.
主要方法:
- 一个多中心数据库的回顾性分析.
- 包括71名接受抗TNFα药物治疗的患者 (63名CL,8名MCL).
- 对临床特征,诊断,疗法和结果的分析.
主要成果:
- 最常见的潜在疾病是炎症性肠病 (33.8%).
- 病变多焦点 (40%) 和大 (>1厘米在94.4%).
- 治疗失败率在MCL (50%) 比CL (8.1%) 更高. 在53.5%的患者中断了生物治疗,在44.7%的患者中恶化了潜在疾病.
结论:
- 停止生物治疗并没有显著影响CL和MCL的治愈率.
- 需要标准化策略来平衡感染控制与潜在炎症疾病的管理.
- 突出了在接受抗TNFα治疗的患者中CL和MCL的临床负担.
相关概念视频
Pulmonary Tuberculosis I
1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
692
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
692
Inflammatory Bowel Disease IV: Pharmacological Management
884
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
884
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
631
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
631


